The study showed that their atrioventricular interval modulation (AVIM) therapy significantly reduced systolic blood pressure in patients with uncontrolled hypertension who require pacemakers. Additionally, a new analysis from the MODERATO II study demonstrated improvements in cardiac function for patients with hypertension and diastolic dysfunction using AVIM therapy. In regulatory developments, the U.S. Food and Drug Administration expanded the eligibility criteria for Orchestra BioMed's BACKBEAT global pivotal study, increasing the potential patient pool significantly. On the financial front, H.C. Wainwright adjusted its price target for Orchestra BioMed to $10.00 from $12.00, while maintaining a Buy rating. Conversely, BTIG downgraded the company's stock from Buy to Neutral, citing concerns about recent decisions and timeline delays.